Free Trial
NASDAQ:BSGM

Biosig Technologies 8/15/2025 Earnings Report

Biosig Technologies logo
$4.11 +0.23 (+5.93%)
Closing price 09/9/2025 04:00 PM Eastern
Extended Trading
$4.22 +0.11 (+2.68%)
As of 07:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biosig Technologies EPS Results

Actual EPS
-$0.74
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.70
One Year Ago EPS
N/A

Biosig Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biosig Technologies Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biosig Technologies' next earnings date is estimated for Thursday, November 13, 2025, based on past reporting schedules.

Conference Call Resources

Biosig Technologies Earnings Headlines

Biosig Technologies trading halted, news pending
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.tc pixel
See More Biosig Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biosig Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biosig Technologies and other key companies, straight to your email.

About Biosig Technologies

Biosig Technologies (NASDAQ:BSGM) is a clinical-stage medical device company developing advanced signal acquisition and processing systems for interventional electrophysiology. Its lead product, the PURE EP™ System, is designed to enhance the quality and reliability of intracardiac recordings during diagnostic and therapeutic procedures for cardiac arrhythmias, including atrial fibrillation and other rhythm disorders.

The PURE EP™ System integrates proprietary hardware and software to deliver higher-fidelity electrograms, helping physicians distinguish true cardiac signals from noise. Biosig Technologies is collaborating with electrophysiology labs and research institutions across the United States to conduct clinical studies and support regulatory filings aimed at expanding market access for its platform.

Founded in the early 2010s and headquartered in New York, Biosig Technologies has pursued U.S. Food and Drug Administration (FDA) regulatory clearance for its flagship device and initiated preparations for European CE mark registration. The company’s pipeline also includes software upgrades and ancillary tools intended to further improve procedural workflows and patient outcomes.

Under the leadership of President and Chief Executive Officer Kenneth L. Londoner, Biosig Technologies is positioning its PURE EP™ platform to address unmet needs in the growing field of cardiac rhythm management. By offering enhanced signal clarity and analytic capabilities, the company aims to become a preferred partner for electrophysiologists seeking innovative technologies to optimize interventional procedures.

View Biosig Technologies Profile

More Earnings Resources from MarketBeat